Our goal at Cardior is to identyfy and counteract the molecular mechanisms of the broad area of iscemic-induced heart faliure as well as specific cardiac diseases such as hypertropic and dilated cardiomyopathies.

Our innovation is based on a novel class of RNA therapeutics targeting so called non-coding RNAs that are able to act on several key disease pathways simultaneously, triggering a concerted therapeutic effect against key hallmarks of heart disease including:

  • Cardiac hypertrophy
  • Fibrosis
  • Impaired contractility
  • Reduced vascularization

Although non-coding RNAs (ncRNAs) are not translated into proteins, they are critical for the regulation of important cellular processes and their dysregulation is a hallmark of many diseases. With its deep knowledge in RNA biology, Cardior has developed a therapeutic approach to restore normal levels and functions of these critical players in the pathological processes of cardiac diseases.

For more information, please contact:

Claus Andersson, PhD

General Partner

Phone: +45 2270 5065